273 related articles for article (PubMed ID: 24642465)
1. Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature.
Facciponte JG; Ugel S; De Sanctis F; Li C; Wang L; Nair G; Sehgal S; Raj A; Matthaiou E; Coukos G; Facciabene A
J Clin Invest; 2014 Apr; 124(4):1497-511. PubMed ID: 24642465
[TBL] [Abstract][Full Text] [Related]
2. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
3. Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression.
Pierini S; Mishra A; Perales-Linares R; Uribe-Herranz M; Beghi S; Giglio A; Pustylnikov S; Costabile F; Rafail S; Amici A; Facciponte JG; Koumenis C; Facciabene A
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563772
[TBL] [Abstract][Full Text] [Related]
4. Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model.
Li C; Chacko AM; Hu J; Hasegawa K; Swails J; Grasso L; El-Deiry WS; Nicolaides N; Muzykantov VR; Divgi CR; Coukos G
Cancer Biol Ther; 2014 Apr; 15(4):443-51. PubMed ID: 24553243
[TBL] [Abstract][Full Text] [Related]
5. HER-2 DNA and protein vaccines containing potent Th cell epitopes induce distinct protective and therapeutic antitumor responses in HER-2 transgenic mice.
Renard V; Sonderbye L; Ebbehøj K; Rasmussen PB; Gregorius K; Gottschalk T; Mouritsen S; Gautam A; Leach DR
J Immunol; 2003 Aug; 171(3):1588-95. PubMed ID: 12874253
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
7. Design of immunogenic and effective multi-epitope DNA vaccines for melanoma.
Cho HI; Celis E
Cancer Immunol Immunother; 2012 Mar; 61(3):343-51. PubMed ID: 21915800
[TBL] [Abstract][Full Text] [Related]
8. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
[TBL] [Abstract][Full Text] [Related]
9. Targeting tumor vasculature: expanding the potential of DNA cancer vaccines.
Ugel S; Facciponte JG; De Sanctis F; Facciabene A
Cancer Immunol Immunother; 2015 Oct; 64(10):1339-48. PubMed ID: 26267042
[TBL] [Abstract][Full Text] [Related]
10. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.
Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J
Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860
[TBL] [Abstract][Full Text] [Related]
11. In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells.
Assudani D; Cho HI; DeVito N; Bradley N; Celis E
Cancer Res; 2008 Dec; 68(23):9892-9. PubMed ID: 19047170
[TBL] [Abstract][Full Text] [Related]
12. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.
Garcia-Hernandez Mde L; Gray A; Hubby B; Kast WM
Cancer Res; 2007 Feb; 67(3):1344-51. PubMed ID: 17283172
[TBL] [Abstract][Full Text] [Related]
13. Optimized DNA vaccines to specifically induce therapeutic CD8 T cell responses against autochthonous breast tumors.
Cho HI; Niu G; Bradley N; Celis E
Cancer Immunol Immunother; 2008 Nov; 57(11):1695-703. PubMed ID: 18253731
[TBL] [Abstract][Full Text] [Related]
14. Immune responses and therapeutic antitumor effects of an experimental DNA vaccine encoding human papillomavirus type 16 oncoproteins genetically fused to herpesvirus glycoprotein D.
Diniz MO; Lasaro MO; Ertl HC; Ferreira LC
Clin Vaccine Immunol; 2010 Oct; 17(10):1576-83. PubMed ID: 20739505
[TBL] [Abstract][Full Text] [Related]
15. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors.
Ji H; Wang TL; Chen CH; Pai SI; Hung CF; Lin KY; Kurman RJ; Pardoll DM; Wu TC
Hum Gene Ther; 1999 Nov; 10(17):2727-40. PubMed ID: 10584920
[TBL] [Abstract][Full Text] [Related]
16. Induction of antigen-specific immune responses against malignant brain tumors by intramuscular injection of sindbis DNA encoding gp100 and IL-18.
Yamanaka R; Xanthopoulos KG
DNA Cell Biol; 2005 May; 24(5):317-24. PubMed ID: 15869409
[TBL] [Abstract][Full Text] [Related]
17. FLK-1-based minigene vaccines induce T cell-mediated suppression of angiogenesis and tumor protective immunity in syngeneic BALB/c mice.
Luo Y; Markowitz D; Xiang R; Zhou H; Reisfeld RA
Vaccine; 2007 Feb; 25(8):1409-15. PubMed ID: 17113202
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with liposome--DNA complexes elicits enhanced antitumor immunity.
U'Ren L; Kedl R; Dow S
Cancer Gene Ther; 2006 Nov; 13(11):1033-44. PubMed ID: 16841080
[TBL] [Abstract][Full Text] [Related]
19. Chimeric DNA vaccine reverses morphine-induced immunosuppression and tumorigenesis.
Cheng WF; Chen LK; Chen CA; Chang MC; Hsiao PN; Su YN; Lee CN; Jeng HJ; Hsieh CY; Sun WZ
Mol Ther; 2006 Jan; 13(1):203-10. PubMed ID: 16140583
[TBL] [Abstract][Full Text] [Related]
20. Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancer.
Williams BB; Wall M; Miao RY; Williams B; Bertoncello I; Kershaw MH; Mantamadiotis T; Haber M; Norris MD; Gautam A; Darcy PK; Ramsay RG
Cancer Immunol Immunother; 2008 Nov; 57(11):1635-45. PubMed ID: 18386000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]